Best combination of CSF biomarkers for predicting cognitive decline and clinical progression: A multi‐cohort study

Amyloid‐β (Aβ) and tau markers have very good prognostic value for Alzheimer’s disease (AD); however, novel neurodegeneration and glial‐related cerebrospinal fluid (CSF) biomarkers may help further improve prognosis. Using multiple CSF biomarkers from a single multi‐panel, we explored the combination of biomarkers that best predicts cognitive decline and clinical progression in three separate cohorts with relevance for clinical practice and trials.